三联原位动脉桥CABG的20年结局
研究更新了1992至2002年间201例接受双侧胸廓内动脉加胃网膜右动脉原位全动脉化CABG患者的临床结局,中位随访19.2年。15年和20年总生存率分别为73.9%和63.5%,免于主要不良心脏事件生存率分别为57.9%和47.9%,支持全动脉化移植的长期获益。
要点
- 三联原位动脉桥CABG术后20年总生存率达63.5%,免于主要不良心脏事件生存率47.9%。
- 20年心肌梗死累积发生率7.8%,经皮再干预9.3%,再次手术7.0%。
- 心源性死亡20年累积发生率12.9%,其他原因死亡15.2%。
核心结论
- 使用双侧胸廓内动脉和胃网膜右动脉作为原位移植物的全动脉化CABG可提供优异的15年和20年生存率及免于心脏事件生存率。
研究设计与样本
- 单中心回顾性队列研究,更新了1992至2002年间接受三联原位动脉桥CABG的201例患者的临床结局,中位随访19.2年(四分位距16.2-20.0年)。
主要发现
- 15年和20年Kaplan-Meier估计总生存率分别为73.9%(95%CI 67.2%-79.5%)和63.5%(95%CI 55.7%-70.4%)。
- 15年和20年免于主要不良心脏事件生存率分别为57.9%(95%CI 50.7%-64.5%)和47.9%(95%CI 40.1%-55.3%)。
- 15年和20年心肌梗死累积发生率分别为7.0%(95%CI 3.5%-10.6%)和7.8%(95%CI 4.0%-11.6%)。
- 15年和20年经皮再干预累积发生率分别为8.6%(95%CI 4.7%-12.5%)和9.3%(95%CI 5.2%-13.3%),再次手术均为7.0%(95%CI 3.5%-10.5%)。
- 15年和20年心源性死亡累积发生率分别为8.6%(95%CI 4.7%-12.6%)和12.9%(95%CI 7.6%-18.2%),其他原因死亡分别为10.8%(95%CI 6.5%-15.2%)和15.2%(95%CI 9.8%-20.6%)。
临床怎么用
- 对于预期寿命较长的三支病变患者,可考虑采用双侧胸廓内动脉加胃网膜右动脉的原位全动脉化CABG以改善远期生存和减少心脏事件。
局限性
- 研究为回顾性设计,样本量201例,且当时该技术主要用于预期寿命较长的患者,结论外推至老年和合并症更重的患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The added value of total arterial revascularization in coronary artery bypass grafting becomes particularly apparent when evaluating long-term results. We previously reported on our 10-year outcomes of total arterial revascularization using bilateral internal thoracic and gastroepiploic arteries as in situ grafts in patients with 3-vessel disease. This study aimed to increase the follow-up period to 20 years. METHODS: We updated clinical outcomes of 201 patients operated on between 1992 and 2002. At that time, the technique was primarily performed in patients with a longer life expectancy. Primary end points were overall survival and freedom from the composite of major adverse cardiac events. Secondary end points were the separate cardiac events. RESULTS: Extended follow-up included all patients. The median follow-up time was 19.2 years (interquartile range, 16.2-20.0). The respective 15- and 20-year Kaplan-Meier estimated survival probabilities were 73.9% (95% confidence interval [CI], 67.2%-79.5%) and 63.5% (95% CI, 55.7%-70.4%) for overall survival and 57.9% (95% CI, 50.7%-64.5%) and 47.9% (95% CI, 40.1%-55.3%) for freedom from major adverse cardiac events. The respective estimated cumulative incidences at 15 and 20 years were 7.0% (95% CI, 3.5%-10.6%) and 7.8% (95% CI, 4.0%-11.6%) for myocardial infarction, 8.6% (95% CI, 4.7%-12.5%) and 9.3% (95% CI, 5.2%-13.3%) for percutaneous reintervention, 7.0% (95% CI, 3.5%-10.5%) and 7.0% (95% CI, 3.5%-10.5%) for reoperation, 8.6% (95% CI, 4.7%-12.6%) and 12.9% (95% CI, 7.6%-18.2%) for cardiac death, and 10.8% (95% CI, 6.5%-15.2%) and 15.2% (95% CI, 9.8%-20.6%) for death from other causes. CONCLUSIONS: The use of in situ bilateral internal thoracic and gastroepiploic arteries provides outstanding 15- and 20-year survival and cardiac event-free survival probabilities. Further studies are needed in older patients with more severe comorbidities. Nevertheless, the results from this and scarce other studies on 15- to 20-year outcomes of total arterial revascularization suggest that cardiac surgeons should embrace the application of total arterial grafting to further reduce the risks of long-term cardiac events, especially during the second decade after surgery.
引用
- Tavilla G, Bruggemans EF, Putter H, et al. Twenty-year outcomes of coronary artery bypass grafting utilizing 3 in situ arterial grafts. J Thorac Cardiovasc Surg. 2018. PMID: 30773385. doi:10.1016/j.jtcvs.2018.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。